Title | Economic Burden, Mortality, and Institutionalization in Patients Newly Diagnosed with Alzheimer's Disease. |
Publication Type | Journal Article |
Year of Publication | 2018 |
Authors | Black, CM, Fillit, H, Xie, L, Hu, X, M Kariburyo, F, Ambegaonkar, BM, Baser, O, Yuce, H, Khandker, RK |
Journal | J Alzheimers Dis |
Volume | 61 |
Issue | 1 |
Pagination | 185-193 |
Date Published | 2018 |
ISSN | 1875-8908 |
Keywords | Aged, Aged, 80 and over, Alzheimer Disease, Cohort Studies, Comorbidity, Cost of Illness, Female, Humans, Institutionalization, Male, Neuropsychological Tests |
Abstract | BACKGROUND: Current information is scarce regarding comorbid conditions, treatment, survival, institutionalization, and health care utilization for Alzheimer's disease (AD) patients. OBJECTIVES: Compare all-cause mortality, rate of institutionalization, and economic burden between treated and untreated newly-diagnosed AD patients. METHODS: Patients aged 65-100 years with ≥1 primary or ≥2 secondary AD diagnoses (ICD-9-CM:331.0] with continuous medical and pharmacy benefits for ≥12 months pre-index and ≥6 months post-index date (first AD diagnosis date) were identified from Medicare fee-for-service claims 01JAN2011-30JUN2014. Patients with AD treatment claims or AD/AD-related dementia diagnosis during the pre-index period were excluded. Patients were assigned to treated and untreated cohorts based on AD treatment received post-index date. Total 8,995 newly-diagnosed AD patients were identified; 4,037 (44.8%) were assigned to the treated cohort. Time-to-death and institutionalization were assessed using Cox regression. To compare health care costs and utilizations, 1 : 1 propensity score matching (PSM) was used. RESULTS: Untreated patients were older (83.85 versus 81.44 years; p CONCLUSION: After controlling for comorbidities, treated AD patients have better survival, lower institutionalization, and sometimes fewer resource utilizations, suggesting that treatment and improved care management could be beneficial for newly-diagnosed AD patients from economic and clinical perspectives. |
DOI | 10.3233/JAD-170518 |
Alternate Journal | J. Alzheimers Dis. |
PubMed ID | 29103033 |